Tolly Epstein, MD
Allergy & Immunology · Indianapolis, INNPI 1851438816
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Blueprint Medicines Corporation at 34.2% of the total.
Across 50 payments — averaging $156.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$3K
- Amgen$2K
- Genentech USA, Inc.$2K
- AstraZeneca$523
- GSK$339
- Shire North American Group Inc$195
- plus $1K from 10 others
Across 6 payments — averaging $38.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$230
What the payments were for
- Consulting fees$3,02839%
- Speaking & faculty fees$2,54433%
- Food & beverage$2,19928%
- Education$461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 2 | $2,677 |
| Amgen | 2 | $1,528 |
| Genentech USA, Inc. | 2 | $1,514 |
| AstraZeneca | 6 | $523 |
| GSK | 13 | $339 |
| Shire North American Group Inc | 2 | $195 |
| Regeneron Healthcare Solutions, Inc. | 2 | $184 |
| Pfizer | 9 | $167 |
| Octapharma USA, Inc. | 2 | $167 |
| Optinose US, Inc. | 1 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $89 |
| Novartis | 3 | $87 |
| Genentech, Inc. | 1 | $72 |
| CSL Behring | 1 | $65 |
| Sanofi | 1 | $49 |
| Bio Products Laboratory USA, Inc. | 1 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,818 in reported general payments places this provider in the 65th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 20 | $1,015,009 |
| XolairOmalizumab | 100 | $367,073 |
| Dupixent PenDupilumab | 36 | $155,074 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 127 | $108,773 |
| Spiriva RespimatTiotropium Bromide | 84 | $77,915 |
| HyqviaIgg/Hyaluronidase,recombinant | 24 | $70,824 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 33 | $70,634 |
| Breo ElliptaFluticasone/Vilanterol | 115 | $70,323 |
| FasenraBenralizumab | 11 | $66,921 |
| Dupixent SyringeDupilumab | 12 | $46,718 |
| Arnuity ElliptaFluticasone Furoate | 74 | $25,673 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $14,481 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $13,945 |
| Epinephrine | 76 | $13,210 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $12,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Hyqvia | $89 | $1,085,83444 claims |
| Genentech, Inc.Xolair | $72 | $367,073100 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $339 | $217,033341 claims |
| AstraZenecaFasenra, Symbicort | $523 | $80,86640 claims |
| CSL BehringHizentra | $65 | $70,63433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Indianapolis
- Steven WiseIndianapolis$137K
- Pinkus GoldbergIndianapolis$89K
- Leanna Marie GershuniIndianapolis$6K
- Craig SewellIndianapolis$4K
- Douglas HortonIndianapolis$4K
- Maria Luisa Pilar ErmitanoIndianapolis$4K
- Jillian BelmonteIndianapolis$1K
- Dana AlhaffarIndianapolis$179
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.